Key result
Clozapine titration led to atypical Neuroleptic Malignant Syndrome without fever, followed by a rapid increase in creatinine kinase levels within a 12-hour timeframe upon rechallenge.
Why the study?
Does clozapine use lead to atypical presentations of Neuroleptic Malignant Syndrome?
Case Report (n=1)
Does clozapine use lead to atypical presentations of Neuroleptic Malignant Syndrome?
Clozapine-induced Neuroleptic Malignant Syndrome may present atypically without fever, suggesting a need for a lower diagnostic threshold in these patients.
No takes yet. Share an insight, caveat, or question.
May support lower NMS diagnostic threshold with clozapine; Level 5 evidence leaves open any practice change.
Agarwal et al. (2021) conducted a case report in Neuroleptic Malignant Syndrome (n=1). Clozapine was evaluated on Development of Neuroleptic Malignant Syndrome. Clozapine titration led to atypical Neuroleptic Malignant Syndrome without fever, followed by a rapid increase in creatinine kinase levels within a 12-hour timeframe upon rechallenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: